Keros Therapeutics (KROS) Competitors

Disc Medicine (NASDAQ:IRON) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Which has more risk and volatility, IRON or KROS?

Disc Medicine has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.

Does the media prefer IRON or KROS?

In the previous week, Disc Medicine had 8 more articles in the media than Keros Therapeutics. MarketBeat recorded 11 mentions for Disc Medicine and 3 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 1.57 beat Disc Medicine's score of 0.74 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is IRON or KROS more profitable?

Disc Medicine has a net margin of 0.00% compared to Keros Therapeutics' net margin of -27,890.94%. Disc Medicine's return on equity of -25.24% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-25.24%	-23.96%
Keros Therapeutics	-27,890.94%	-41.74%	-38.42%

Which has stronger valuation & earnings, IRON or KROS?

Disc Medicine has higher earnings, but lower revenue than Keros Therapeutics. Disc Medicine is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$76.43M	-$3.99	-13.12
Keros Therapeutics	$3.55M	123.29	-$152.99M	-$5.01	-2.15

Do analysts prefer IRON or KROS?

Disc Medicine presently has a consensus price target of $93.80, indicating a potential upside of 79.14%. Keros Therapeutics has a consensus price target of $42.33, indicating a potential upside of 292.34%. Given Keros Therapeutics' higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.09
Keros Therapeutics	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.57

Do insiders and institutionals have more ownership in IRON or KROS?

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 4.2% of Disc Medicine shares are owned by company insiders. Comparatively, 22.9% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community believe in IRON or KROS?

Keros Therapeutics received 5 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 86.57% of users gave Disc Medicine an outperform vote while only 70.00% of users gave Keros Therapeutics an outperform vote.

Company	Underperform	Outperform
Disc Medicine	Outperform Votes 58 86.57%	Underperform Votes 9 13.43%
Keros Therapeutics	Outperform Votes 63 70.00%	Underperform Votes 27 30.00%

Summary

Disc Medicine beats Keros Therapeutics on 11 of the 18 factors compared between the two stocks.